Pharmacogenetic analysis to investigate the association between efficacy and neurotoxicity of oxaliplatin and single nucleotide polymorphisms

Pharmacogenetic analysis to investigate the association between efficacy and neurotoxicity of oxaliplatin and single nucleotide polymorphisms - Pharmacogenetic analysis of oxaliplatin

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000002490

Enrollment

133

Registered

2009-11-10

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed colorectal cancer patients with measurable liver metastasis who received oxaliplatin-based chemotherapy as first line treatment 2. Written informed consent is provided

Exclusion criteria

Exclusion criteria: The patients with a history of adjuvant chemotherapy using oxaliplatin

Design outcomes

Primary

Measure	Time frame
To investigate the association between the efficacy of oxaliplatin for liver metastasis and SNP of ERCC1-118 in colorectal cancer patients.	—

Secondary

Measure	Time frame
To investigate the association between the oxaliplatin-induced neurotoxicity and SNP of GSTP1-105.	—

Countries

Japan

Outcome results